StockNews.AI
VRCA
StockNews.AI
169 days

Verrica Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results and Provide a Corporate Update on March 11, 2025

1. Verrica will host a conference call on March 11, 2025. 2. The call will cover Q4 and full year 2024 financial results. 3. YCANTH (VP-102) treats molluscum contagiosum, affecting about 6 million Americans. 4. Verrica partners with Lytix Biopharma to develop skin cancer treatment VP-315. 5. The webcast will be available for 90 days post-event for investors.

Earnings
-7.95%Current Return
VS
-2.68%S&P 500
$0.649103/03 07:05 AM EDTEvent Start
$0.597503/04 01:34 PM EDTLatest Updated
4m saved
Insight
Article

FAQ

Why Bullish?

Upcoming financial results may indicate growth, given the unique market position of YCANTH.

How important is it?

Key corporate updates and product developments signal potential investment opportunity.

Why Short Term?

Immediate investor interest expected due to the approaching earnings call.

Related Companies

LYTIXPFEJNJ
March 03, 2025 07:00 ET  | Source: Verrica Pharmaceuticals Inc. WEST CHESTER, Pa., March 03, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that it will host a conference call and live webcast at 4:30 p.m. ET on Tuesday, March 11, 2025, to discuss the Company's financial results for the fourth quarter and full year ending December 31, 2024, and provide a corporate update. Individuals may participate in the live call via telephone by dialing 1-800-445-7795 (domestic) or 1-785-424-1699 (international) and using the conference ID: VERRICA. Participants are asked to dial in 10 minutes before the start of the call to register. A live audio webcast of the call be accessed by visiting the investor relations section of the Company’s website, www.verrica.com, or by clicking here. A replay of the webcast will be archived on Verrica’s website for 90 days following the event. About Verrica Pharmaceuticals Inc. Verrica is a dermatology therapeutics company developing medications for skin diseases requiring medical interventions. Verrica’s product YCANTH (VP-102) (cantharidin), is the first and only commercially available treatment approved by the FDA to treat adult and pediatric patients two years of age and older with molluscum contagiosum, a highly contagious viral skin infection affecting approximately 6 million people in the United States, primarily children. YCANTH (VP-102) is also in development to treat common warts, one of the largest remaining unmet needs in medical dermatology. Verrica has also entered a worldwide license agreement with Lytix Biopharma AS to develop and commercialize VP-315 (formerly LTX-315 and VP-LTX-315) for non-melanoma skin cancers including basal cell carcinoma and squamous cell carcinoma. For more information, visit www.verrica.com. FOR MORE INFORMATION, PLEASE CONTACT: Investors: John J Kirby Interim Chief Financial Officer jkirby@verrica.com Kevin Gardner LifeSci Advisors kgardner@lifesciadvisors.com Chris Calabrese LifeSci Advisors ccalabrese@lifesciadvisors.com

Related News